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Introduction
Carcinomas of the head and neck, including cancers
originating from the oral cavity, oropharynx, hypophar-
ynx and larynx, represent the sixth most frequent type
of cancer in the world. The most common type of
head and neck cancer is squamous cell carcinoma
(HNSCC), which accounts for more than 90% of oral
malignancies.1 The main etiologic factors in the West
include alcohol consumption, tobacco use, and poor
oral hygiene; whereas in Asia it is commonly linked to
the habit of betel nut chewing (e.g. in Taiwan).2–4
The management of metastatic/recurrent HNSCC
remains a major obstacle for medical oncologists and
surgeons because of its treatment resistance and poor
prognosis despite major technological advances in
HNSCC treatment in recent years.1,5
A number of chemotherapeutic agents have activity
against HNSCC, including methotrexate, cisplatin,
bleomycin, 5-fluorouracil (5-FU), docetaxel, and pac-
litaxel. To date, cisplatin has been associated with in-
creased survival versus supportive care.6 Cisplatin/5-FU
combination therapy is the most common treatment
for patients with unresectable and recurrent HNSCC
after radical surgery or radiotherapy. However, con-
ventional cisplatin/5-FU chemotherapy is associated
with significant dose-limiting grade 3–4 mucositis and
prolonged administration time, which are problematic
in this patient population.7
Weekly high-dose 5-FU (2,000–2,600mg/m2/day,
continuous infusion for 24 hours, per 1 week) has
been shown to have a relatively lower non-hematologic
toxicity compared with traditionally administrated 5-FU
in other cancers.8–14 To eliminate the dose-limiting
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toxicity of the conventional cisplatin/5-FU regimen
(5-FU: 1,000 mg/m2/day, continuous infusion for
96 hours, per 3 weeks) used in metastatic/recurrent
HNSCC, we changed the conventional 5-FU regi-
men to biweekly high-dose 5-FU (2,000 mg/m2/
day, continuous infusion for 48 hours, per 2 weeks).
In addition, both methotrexate and leucovorin have
been reported to have a chemomodulating effect on
5-FU.15–18 We therefore designed a regimen that com-
bined cisplatin with biweekly high-dose 5-FU modu-
lated by both methotrexate and leucovorin (MPFL)
to decrease toxicity and maximize the effect of high-
dose 5-FU in metastatic/recurrent HNSCC patients.
Methods
Patient eligibility
From September 2001 to December 2003, patients
with recurrent/metastatic squamous cell carcinoma of
the oral cavity, oropharynx, hypopharynx, and larynx in
Taipei Veterans General Hospital, Taiwan, were enrolled
in this study. The protocol was approved by the insti-
tutional review board. The eligibility criteria were distant
metastasis or locoregional recurrent HNSCC (unre-
sectable and unsuitable for radiotherapy). The inclu-
sion criteria were: radiologically assessable disease; life
expectancy > 3 months; Eastern Cooperative Group
performance status ≤ 2; adequate hematologic, renal,
and liver function; and signed informed consent. The
exclusion criteria were: brain metastasis proven by com-
puted tomography (CT); significant comorbidities with
major organ dysfunction; other malignancy except basal
cell skin carcinoma or cervical carcinoma in situ.
Treatment scheme
After vigorous hydration, urinary alkalinization, and ad-
ministration of antiemetics, patients were treated with
cisplatin 40 mg/m2/day continuous infusion for 24
hours on day 1; high-dose 5-FU 2,000mg/m2/day and
leucovorin 100 mg/m2/day continuous infusion for
48 hours on days 1 and 2; methotrexate 40 mg/m2/
day bolus infusion for 4 hours before 5-FU on day 1.
The treatment was repeated every 2 weeks in a cycle.
Evaluation of treatment response
Before initiation of chemotherapy, patients were eval-
uated with a complete history and physical examination,
performance status recording, complete blood cell
count, and serum biochemistries. CT was performed to
evaluate target lesions. Other examinations were per-
formed only in the presence of a clinical indication.
Laboratory tests were repeated before the start of each
cycle. Evaluation for tumor response was performed
every 3 months with CT scan. Tumor response was
defined according to RECIST (Response Evaluation
Criteria In Solid Tumors) criteria.19
Evaluation of toxicity and dose adjustment
Toxicities were graded according to the National Cancer
Institute Common Toxicity Criteria (NCI-CTC) ver-
sion 2.0 and were evaluated before each treatment cycle.
Treatment was withheld for 1 week if neutrophil count
was < 1,500/mL and platelet count was < 75,000/mL
at the time of chemotherapy recycling. If full hemato-
logic recovery did not occur within 2 weeks, the treat-
ment was discontinued. If grade 4 hematologic toxicity
occurred, the protocol required a reduction to 75% of
the planned dose in subsequent courses, even after full
recovery. Granulocyte colony-stimulating factor was not
given prophylactically but was permitted in patients with
grade 3–4 neutropenia. Cisplatin dose was reduced by
50% when creatinine clearance (CCr) was 40–60 mL/
min, and was withheld when CCr was < 40 mL/min.
If grade 3 or 4 mucositis developed, the dose of
methotrexate and 5-FU was reduced by 25% in the
subsequent cycle.
Statistical analysis
SPSS version 13 (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Kaplan-Meier estimate was
used for survival analysis, and log-rank test was used
for comparison between group overall survival rates.
The response analysis of each clinical factor was com-
pared using the χ2 test (for expected values > 5) or
Fisher’s exact test (for expected values ≤ 5) for cate-
gorical variables. The level of statistical significance was
set at a 2-sided p value < 0.05 for all tests.
Results
Patient characteristics and treatment response
From September 2001 to December 2003, 28 patients
(26 men, 2 women) were enrolled in the study. Among
the study population, 11 patients had primary metasta-
tic disease without any treatment before diagnosis and
17 patients had locoregional recurrence after initial
surgical resection followed by postoperative concurrent
chemoradiation (CCRT). The median follow-up period
was 15 months, and the median number of treatment
cycles was 4 (range, 2–9). The median age of the
patients was 52 years (range, 34–76 years). The patient
characteristics are listed in Table 1.
Regarding treatment response, there was no 
complete response. Seven (25%) patients had a partial
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response (PR), whereas 4 (14%) achieved stable dis-
ease (SD). The overall response rate and disease control
rate (defined as complete response [CR] + PR + SD)
were 25% and 39%, respectively. No significant corre-
lation could be demonstrated between the clinical fac-
tors (primary sites, metastatic sites, age, sex, types of
previous treatment) and treatment response (data not
shown).
Survival analysis
The Kaplan-Meier estimated overall survival curve for
the 28 patients is shown in Figure 1A. The median sur-  
vival for all patients was 7.9 months, which was similar
to other reports (6-month median survival time in most
studies conducted in the last 20 years).5,20–23 To evalu-
ate the effect of disease controlled by MPFL on over-
all survival, survival analysis using the log-rank test was
performed in patients grouped as the disease-control
group (n = 11) and disease-progression group (n = 17).
Significantly improved survival rate was demonstrated
in the disease-control group (Figure 1B). The median
survival periods of the disease-control and disease-
progression groups were 12.0 months and 5.3 months
(p < 0.001), respectively.
Adverse events
The treatment-related toxicity of MPFL in all patients
is shown in Table 2. Only 3 (10.7%) patients developed
grade 3–4 neutropenia, whereas no grade 3–4 non-
hematologic toxicity was identified. A low incidence
of mucositis was noted.
Discussion
Despite advances in the treatment of patients with
HNSCC, recurrent/metastatic HNSCC carries a poor
prognosis, with a median overall survival of around
5.0–8.2 months.5,7,20–23 Till now, the survival benefit
of chemotherapy for recurrent/metastatic HNSCC is
still unsatisfactory, with a 1-year survival rate of around
40%.7 For more than a decade, the most common
Table 1. Characteristics of the 28 patients
Age, yr
Range 34–76
Median 52
Sex, n
Male 26
Female 2
Primary tumor site, n
Hypopharynx 17
Larynx 4
Oral cavity 2
Oropharynx 5
Performance status (ECOG), n
0–1 12
2 16
Disease status, n
Distant metastasis 11
Lung 7
Liver 3
Bone 1
Locoregional recurrence 17
ECOG = Eastern Cooperative Oncology Group.
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Figure 1. Kaplan-Meier plots: (A) overall survival; (B) overall survival related to treatment response. PR = partial remission; SD = stable
disease; PD = progressive disease.
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chemotherapy for recurrent/metastatic HNSCC has
been the conventional cisplatin/5-FU regimen.5,7,18,20–23
However, the dose-limiting toxicity has a negative im-
pact on the quality of life of advanced HNSCC cases.
Newer treatment protocols should be developed to de-
crease the toxicity and improve the quality of life of
HNSCC patients without compromising the effective-
ness of treatment (e.g. treatment response, survival). We
therefore designed the MPFL regimen in order to test
its effectiveness and tolerability in advanced HNSCC.
The most important observation with regard to our
MPFL regimen was the lower grade 3–4 mucositis (0%).
Mucositis is the major dose-limiting non-hematologic
toxicity of the conventional 5-FU schedule, with the in-
cidence of grade 3–4 toxicity ranging from 6% to 31%
(Table 3).5,8–10,12,13,20–24 This adverse event may be
related to the longer duration of 5-FU continuous infu-
sion. In the previous studies of other cancers shown in
Table 3, the rate of grade 3–4 mucositis was lower in
high-dose 5-FU groups than in conventional 5-FU
groups (0–5.9% vs. 6–31%). The reason for the lower
mucositis rate is possibly that the administration of bi-
weekly high-dose infusional 5-FU permits phosphatase
recovery or activation in mucosa cells. In a previous ani-
mal study, 5-FU alone inhibited the activity of several
enzymes, including thymidine-kinase, maltase and
alkaline-phosphatase. The nadir of enzyme activity was
between 24 and 96 hours after 5-FU administration,
and complete regeneration took a week.25 It is known
that adequate phosphatase activity to metabolize
FdUMP is a common mechanism for mucosa cell recov-
ery. This result might contribute to better life quality.
Methotrexate alone has also been used in the past
because of its low dose-limiting toxicity, but lower
response rate has restricted its clinical application.
Forastiere et al reported that the response rate to
Table 2. Adverse events in the 28 patients*
Toxicity
NCI-CTC grade
1 2 3 4
Hematologic
Anemia 5 (17.9) 3 (10.7) 0 (0) 0 (0)
Neutropenia 8 (28.6) 3 (10.7) 3 (10.7) 0 (0)
Thrombocytopenia 4 (14.3) 1 (3.6) 0 (0) 0 (0)
Infection 1 (3.6) 0 (0) 0 (0) 0 (0)
Renal 2 (7.1) 2 (7.1) 0 (0) 0 (0)
Liver 1 (3.6) 0 (0) 0 (0) 0 (0)
Mucositis 5 (17.9) 2 (7.1) 0 (0) 0 (0)
Nausea/vomiting 4 (14.3) 2 (7.1) 0 (0) 0 (0)
Diarrhea 5 (17.9) 0 (0) 0 (0) 0 (0)
Cutaneous 3 (10.7) 0 (0) 0 (0) 0 (0)
*Data presented as n (%). NCI-CTC = National Cancer Institute Common Toxicity Criteria (version 2.0).
Table 3. Median survival, response rate, grade 3–4 neutropenia and mucositis in selected trials, including our MPFL regimen
5-FU schedule 
Median Response Grade 3–4 Grade 3–4 
References
survival (mo) rate (%) neutropenia (%) mucositis (%)
Non head & neck neoplasm 
Weekly HD 5-FU* – – 0–34 0–5.9 8, 10, 12, 13, 24
Head & neck neoplasm
NPC
Weekly HD 5-FU* – – 0 0 9
Non-NPC
Conventional 5-FU†/cisplatin 5.5–8.7 25–47.1 8.2–67 6–31 5, 20, 21, 22, 23
Biweekly HD 5-FU‡/cisplatin (MPFL§) 7.9 25 10.7 0
*More than 2,000 mg/m2/day, continuous infusion 1 day weekly; †1,000 mg/m2/day, continuous infusion for 96 hours per 3 weeks; ‡more than
2,000 mg/m2/day, continuous infusion 2 days biweekly; §combination of cisplatin and biweekly high-dose 5-FU modulated by methotrexate and leucovorin.
5-FU = 5-fluorouracil; HD = high-dose; NPC = nasopharyngeal carcinoma.
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methotrexate alone was 10% and the rate of grade 3–4
mucositis was 10%.20 Other new-generation chemother-
apeutic agents, such as taxanes, have recently been used
in the management of recurrent/metastatic HNSCC,
and no grade 3–4 mucositis was noted. However, the
high incidence of grade 3–4 hematologic toxicity and
low cost-effectiveness has limited its clinical application.
Gibson et al reported a 26% response rate in patients
treated with a combination of paclitaxel and cisplatin;
55% of paclitaxel/cisplatin-treated patients developed
grade 3–4 neutropenia, and 4% of patients died of
infection.21
In our study, the therapeutic effect of the MPFL
regimen for metastatic/recurrent HNSCC was not
superior to those of previous studies, with a modest
response rate of 25% and median survival of 7.9
months.5,20–23 There was also some disadvantage in that
the continuous parenteral administration of cisplatin
and 5-FU require that patients be hospitalized for at
least 3 days. However, the toxicity profile suggested
that the regimen was well tolerated. Only 3 (10.7%)
patients had grade 3 neutropenia, none had grade 4
neutropenia or grade 3–4 non-hematologic toxicities,
none had severe treatment-related morbidity, and none
died because of the treatment.
In conclusion, our results demonstrated that the
MPFL regimen has better tolerability without com-
promising treatment effectiveness (e.g. treatment re-
sponse, survival) compared with previous reports, and
the survival benefit was observed in the disease-control
group. This indicates that the MPFL regimen should
be considered for late-stage HNSCC cases as it is better
tolerated and its effectiveness is comparable to other 
regimens. We suggest that new multiagent protocols be
studied for effectiveness on survival and quality of life.
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